Precigen, Inc. (PGEN) News
Filter PGEN News Items
PGEN News Results
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PGEN News From Around the Web
Below are the latest news stories about Precigen Inc that investors may wish to consider to help them evaluate PGEN as an investment opportunity.
H.C. Wainwright Thinks Precigen’s Stock is Going to RecoverIn a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $10.00. The company's shares closed last Tuesday at $2.16, close to its 52-week low of $1.91. According to TipRanks.com, Ramakanth is a 4-star analyst with an average return of 11.0% and a 39.6% success rate. Ramakanth covers the Healthcare sector, focusing on stocks such as Cellectar Biosciences, Harpoon Therapeutics, and Corcept Therapeutics. Currently, the analyst consensus on Precigen is a Strong Buy with an average price target of $13.33, a 522.9% upside from current levels. |
Analysts Offer Insights on Healthcare Companies: Cassava Sciences (SAVA), Precigen (PGEN) and BioCardia (BCDA)There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cassava Sciences (SAVA – Research Report), Precigen (PGEN – Research Report) and BioCardia (BCDA – Research Report) with bullish sentiments. Cassava Sciences (SAVA) In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Cassava Sciences, with a price target of $180.00. The company's shares closed last Tuesday at $40.97, close to its 52-week low of $31.44. According to TipRanks. |
Precigen GAAP EPS of -$0.13 beats by $0.01, revenue of $24.22M beats by $1.98MPrecigen press release (PGEN): Q4 GAAP EPS of -$0.13 beats by $0.01.Revenue of $24.22M (+25.3% Y/Y) beats by $1.98M.Cash, cash equivalents, and short-term and long-term… |
Precigen Reports Fourth Quarter and Full Year 2021 Financial ResultsPrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced fourth quarter and full year 2021 financial results. |
Further weakness as Precigen (NASDAQ:PGEN) drops 10% this week, taking five-year losses to 88%We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really... |
AGF Investments LLC Buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The ...Investment company AGF Investments LLC (Current Portfolio) buys Health Care Select Sector SPDR, Financial Select Sector SPDR, The Energy Select Sector SPDR Fund, Paratek Pharmaceuticals Inc, Hello Group Inc, sells Industrial Select Sector SPDR, Consumer Staples Select Sector SPDR, Utilities Select Sector SPDR ETF, Microsoft Corp, UnitedHealth Group Inc during the 3-months ended 2021Q4, according to the most recent filings of the investment company, AGF Investments LLC. |
It's been a tough year so far on Wall Street. These D.C.-area companies have suffered the biggest hits.It's been a bruising start to 2022 on Wall Street — and the tumble moved into correction territory Monday morning with the S&P 500 falling about 10% from a recent high. The markets have made their biggest declines since the early uncertainty of the Covid-19 pandemic. |
Wells Fargo Thinks Precigen’s Stock is Going to RecoverIn a report issued on January 18, Nick Abbott from Wells Fargo reiterated a Buy rating on Precigen (PGEN – Research Report), with a price target of $17.00. The company's shares closed last Wednesday at $3.00, close to its 52-week low of $2.99. According to TipRanks.com, Abbott 's ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -42.7% and a 0.0% success rate. Abbott covers the Healthcare sector, focusing on stocks such as Iovance Biotherapeutics, Cellectis SA, and MEI Pharma. Precigen has an analyst consensus of Strong Buy, with a price target consensus of $13.33, which is a 331.4% upside from current levels. |
Precigen provides pipeline updates for 2022Precigen (PGEN) presented pipeline updates at the 40th Annual J.P |
Precigen Provides Pipeline and Corporate Updates at the 40th Annual J.P. Morgan Healthcare ConferencePrecigen, Inc. (Nasdaq: PGEN), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today presented pipeline and corporate updates at the 40th Annual J.P. Morgan Healthcare Conference. Helen Sabzevari, PhD, President and CEO of Precigen, presented a summary of 2021 achievements and set forth Precigen's goals for 2022. |